We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+25.69%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.85B
AUM Growth
+$604M
Cap. Flow
+$513M
Cap. Flow %
18.04%
Top 10 Hldgs %
65.03%
Holding
69
New
10
Increased
6
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$320M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$126M
3
TERN
Terns Pharmaceuticals
TERN
+$58.6M
4
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$35.9M
5
DSGN icon
Design Therapeutics
DSGN
+$17.9M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$20.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$18.5M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$17M
4
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$10.2M
5
MTNB icon
Matinas BioPharma
MTNB
+$8.77M

Sector Composition

Rank Sector Weight
1 Healthcare 85.49%
2 Materials 8.84%
3 Financials 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRCL
26
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$23.5M 0.82%
+1,522,994
New +$35.9M
ZLAB icon
27
Zai Lab
ZLAB
$2.05B
$23.4M 0.82%
175,000
– –
KDMN
28
DELISTED
Kadmon Holdings, Inc.
KDMN
$22.6M 0.8%
5,817,459
– –
ARQT icon
29
Arcutis Biotherapeutics
ARQT
$3.24B
$21.5M 0.76%
744,370
-122,800
-14% -$3.83M
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$19.5M 0.69%
673,280
+39,854
+6% +$1.21M
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$18.7M 0.66%
1,206,266
– –
CRIS icon
32
Curis
CRIS
$10M
$17.6M 0.62%
3,884
+384
+11% +$1.61M
NKTX icon
33
Nkarta
NKTX
$154M
$16.9M 0.59%
512,225
– –
CYTK icon
34
Cytokinetics
CYTK
$10.4B
$16.3M 0.57%
700,000
– –
DSGN icon
35
Design Therapeutics
DSGN
$799M
$15.9M 0.56%
+530,991
New +$17.9M
EIGR
36
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$15.9M 0.56%
59,709
– –
KURA icon
37
Kura Oncology
KURA
$816M
$14.8M 0.52%
525,262
– –
MREO
38
Mereo BioPharma
MREO
$50.4M
$14.2M 0.5%
4,220,938
– –
LRMR icon
39
Larimar Therapeutics
LRMR
$413M
$11.7M 0.41%
799,662
– –
CGEM icon
40
Cullinan Oncology
CGEM
$999M
$10.4M 0.37%
+250,000
New +$10.1M
ORTX
41
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$9.63M 0.34%
132,574
– –
ASLN
42
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$9.52M 0.33%
+71,023
New +$9M
ARWR icon
43
Arrowhead Research
ARWR
$12.1B
$9.11M 0.32%
137,411
-67,680
-33% -$5.25M
ZYME icon
44
Zymeworks
ZYME
$1.68B
$9.03M 0.32%
286,064
– –
DYN icon
45
Dyne Therapeutics
DYN
$4.71B
$8.97M 0.32%
577,642
+262,642
+83% +$5.08M
CDXS icon
46
Codexis
CDXS
$156M
$8.88M 0.31%
388,144
– –
CALT
47
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$8.57M 0.3%
311,030
– –
IMVT icon
48
Immunovant
IMVT
$7.91B
$8.55M 0.3%
532,847
+185,185
+53% +$4.88M
QTTB icon
49
Q32 Bio
QTTB
$451M
$8.03M 0.28%
47,397
– –
STSA
50
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$7.28M 0.26%
+1,232,394
New +$7.47M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Vivo Capital held 69 positions worth $2.85B, up 27% from $2.24B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Vivo Capital deployed $513M of net new capital in Q1 2021, opening 10 new positions and adding to 6 existing holdings. Its largest new stake was Instil Bio: 624,339 shares worth $313M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Materials and Financials.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $20.3M trimmed.

  • Vivo Capital's largest Q1 2021 buy was Instil Bio: 624,339 shares worth $313M.
  • Vivo Capital added most to KalVista Pharmaceuticals in Q1 2021, an estimated $6.44M increase.
  • Vivo Capital's biggest Q1 2021 reduction was Ascendis Pharma A/S, cutting an estimated $20.3M.
  • Vivo Capital fully exited Rocket Pharmaceuticals in Q1 2021, selling an estimated $17M.
  • Vivo Capital's ten largest holdings make up 65% of its $2.85B portfolio in Q1 2021.
  • Vivo Capital opened 10 new positions and closed 6 in Q1 2021.
  • Vivo Capital's portfolio value rose 27% quarter-over-quarter to $2.85B.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.